Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01120964|
Recruitment Status : Completed
First Posted : May 11, 2010
Last Update Posted : January 24, 2017
This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery. Participants will be randomly assigned to either L-citrulline or a placebo (a substance that has no medicine in it).
Citrulline is a protein building block in the body that can convert into another substance, nitric oxide (NO), which controls blood pressure in the lungs. Increased blood pressure in the lungs can be an important surgical problem; it may also lead to problems following surgery, such as severe high blood pressure in the lungs (pulmonary hypertension), increased time spent on a breathing machine, and a longer stay in the intensive care unit (ICU). The hypothesis of this study is that perioperative supplementation with intravenous citrulline will increase plasma citrulline, arginine and NO metabolites and prevent elevations in the postoperative PVT leading to a decrease in the duration of postoperative invasive mechanical ventilation.
The objective of this study is to determine in a randomized placebo controlled phase IB multicenter clinical trial if a revised protocol of intravenous L-citrulline delivery given perioperatively achieves a plasma citrulline level of > 100 umol/L in children undergoing surgical repair of an atrial septal defect,ventricular septal defect or an atrioventricular septal defect.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Septal Defect Ventricular Septal Defect Atrioventricular Septal Defect||Drug: Intravenous L-Citrulline Drug: Placebo of Intravenous L-Citrulline||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass|
|Study Start Date :||September 2010|
|Primary Completion Date :||April 2012|
|Study Completion Date :||April 2012|
|Experimental: Intravenous L-Citrulline||
Drug: Intravenous L-Citrulline
150mg bolus X 1 after initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 umol/L or placebo to the filtration and hemoconcentration fluid utilized during cardiopulmonary bypass in addition to a 20mg/kg bolus 30 minutes after separation from cardiopulmonary bypass immediately followed by a continuous infusion of 9mg/kg/hr IV, and ending at 48 hours continuous infusion or discharge from the PCCU.
|Placebo Comparator: Placebo of Intravenous L-Citrulline||
Drug: Placebo of Intravenous L-Citrulline
Placebo of Intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
- To determine if L-citrulline given perioperatively achieves a plasma citrulline level of > 100 umol/L in children undergoing surgical repair of an atrial septal defect, a ventricular septal defect or an atrioventricular septal defect. [ Time Frame: Measured in seven blood sample time points from the beginning of surgery until end of IV Citrulline Infusion; at either 48 hours postoperatively or at extubation, whichever comes first. ]Citrulline Blood Levels : 1. Baseline sample in OR prior to Cardiopulmonary Bypass prior to admistration of first bolus of Citrulline or Placebo 2. Immediately after Bolus 1 administered in Operating Room. 3. 30 minutes after separation from Cardiopulmonary Bypass; immediately prior to administration of Bolus 2 and start of continuous infusion of Citrulline or Placebo. 4. Six hours after after start of infusion. 5. 12 hours after start of infusion. 6. 24 hours after start of infusion. 7. 48 hours after start of infusion; or whenever infususion is discontinued if prior to 48 hours.
- Duration of postoperative mechanical ventilation in hours compared between treatment groups [ Time Frame: Measured in hours from the end of surgery until extubation ]
- Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours [ Time Frame: Measured in hours from the end of surgery until extubation ]
- Postoperative intravenous inotrope score [ Time Frame: Measured at 48 hours ]
- Length and volume of chest tube drainage [ Time Frame: Measured in hours from the end of surgery until removal of chest tubes ]
- Length of ICU stay [ Time Frame: Measured in hours from the end of surgery to discharge from ICU ]
- Length of hospitalization [ Time Frame: Measured from the day of surgery until discharge from hospital ]
- Survival [ Time Frame: Measured at 28 days post surgical repair ]
- The incidence of clinically significant hypotension. [ Time Frame: Mean Arterial Blood pressure as continuously monitored postoperatively in the PCCU during Citrulline or Placebo infusion. ]Age specific mean aterial blood pressrue limits compared between the citrulline and placebo groups will be used to determine significant hypotension.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01120964
|United States, Missouri|
|Washington University Children's Hospital|
|St. Louis, Missouri, United States, 63110|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center|
|Cincinnati, Ohio, United States, 45229|
|Study Chair:||Frederick E Barr, MD||Batson Children's Hospital, University of Mississippi Medical Center|
|Principal Investigator:||Catherine Krawczeski, MD||Children's Hospital Medical Center, Cincinnati|
|Principal Investigator:||Allan Doctor, MD||St. Louis Children's Medical Center|